Use this interactive tool, led by Professor Dorota Religa, Dr Carolyn Clevenger, Professor Robert Perneczky, Professor Hitoshi Shimada and Dr Chuck Vega, to create your personalized summary of best practices and clinical evidence on biomarkers in early-stage Alzheimer’s disease.
Liked this educational activity?
General information
Title: Build your own infographic
Release date: March 26, 2026
Estimated time: 10 minutes
Target audience
This activity is primarily aimed at dementia specialists, neurologists, geriatricians, geriatric psychiatrists, primary care providers, imaging physicians, advanced practice providers (NPs/PAs), but is relevant to all members of the multidisciplinary team that manage patients with Alzheimer’s disease.
Learning objectives
After completing this module, the participant should be better able to:
- Evaluate the utility of current and emerging biomarkers to support an accurate diagnosis of early-stage Alzheimer’s disease
- Interpret the results of imaging and fluid biomarker tests for early-stage Alzheimer’s disease
- Apply biomarker testing to guide treatment selection for disease-modifying therapies and appropriate treatment monitoring
Faculty
Professor Dorota Religa (Program Director)
Professor / Senior Consultant
Karolinska Institutet, Sweden
Disclosures
Nothing to disclose
Dr Carolyn Clevenger
Professor and Executive Director
Integrated Memory Care, Emory University, United States
Disclosures
Consultant/Advisory Board: Braincheck, Eli Lilly, Novo Nordisk, Otsuka
Professor Robert Pernezcky
Professor of Translational Dementia Research
LMU Hospital, LMU Munich, Germany
Disclosures
Employee/Owner: Medotrax
Grant/Research Support: GSK, Roche
Speakers Bureau/Honoraria for non-CME: Biogen, Eisai, Eli Lilly, Roche, Schwabe, Tabuk
Consultant/Advisory Board: Biogen, Bristol-Myers Squibb, Eisai, Eli Lilly, Roche
Professor Hitoshi Shimada
Professor
Brain Research Institute, Niigata University, Japan
Disclosures
Grant/Research Support: Shimadzu, Splink
Speakers Bureau/Honoraria for non-CME: Biogen, Eisai, Eli Lilly, Kowa, Kyowa Kirin, Medi-Physicas, Nihon, PDR pharma, Shimadzu, Takeda
Dr Chuck Vega
Clinical Professor of Family Medicine
UC Irvine, United States
Disclosures
Consultant/Advisory Board: Boehringer Ingelheim, Exact Sciences
All relevant financial relationships have been mitigated.
